Michael Yu, Innovent CEO (Anthony Kwan/Bloomberg via Getty Images)

As US re­view of Eli Lil­ly-part­nered PD-1 gets un­der­way, In­novent touts an­oth­er front­line win in Chi­na

When Eli Lil­ly inked a $1 bil­lion-plus deal to grab ex-Chi­na com­mer­cial­iza­tion rights for In­novent’s PD-1 Tyvyt (sin­til­imab), the part­ners hailed the “clin­i­cal pro­file” of the drug they co-de­vel­oped and vowed to keep ex­plor­ing its po­ten­tial across tu­mor types.

One year lat­er, Tyvyt has notched an­oth­er big win on its home turf.

Suzhou-based In­novent says at the in­ter­im analy­sis, the drug hit the pri­ma­ry end­point of over­all sur­vival in ORI­ENT-16, a Phase III clin­i­cal tri­al for un­re­sectable, lo­cal­ly ad­vanced, re­cur­rent or metasta­t­ic gas­tric or gas­troe­sophageal junc­tion (GEJ) ade­no­car­ci­no­ma. Specif­i­cal­ly, it pits a com­bi­na­tion of the PD-1 in­hibitor and chemother­a­py (ox­ali­platin and capecitabine) against chemo alone.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.